Start Date
December 31, 2010
Primary Completion Date
December 31, 2011
Study Completion Date
December 31, 2011
plasmapheresis and IVIG
Plasmapheresis with either 5% human albumin or FFP replacement, plus IVIG 100mg/kg IV after each PP session, every other day x 5 treatments
recombinant C1 inhibitor
100units/kg IV for seven consecutive days (once daily on PP/IVIG days, twice daily on non-PP/IVIG days).
University of Wisconsin, Madison
Lead Sponsor
University of Wisconsin, Madison
OTHER
Pharming Technologies B.V.
INDUSTRY